Lenvatinib
Generic name: Lenvatinib
Dosage form: oral capsule (10 mg; 12 mg daily-dose; 14 mg daily-dose; 18 mg daily-dose; 20 mg daily-dose; 24 mg daily-dose; 4 mg; 8 mg daily-dose)
Usage of Lenvatinib
Lenvatinib is a kinase inhibitor used to treat certain types of cancer. Kinase inhibitors are enzyme inhibitors that blocks the action of one or more protein kinases.
Lenvatinib is used to treat thyroid cancer. It is usually given after radioactive iodine has been tried without success.
Lenvatinib is used together with everolimus (Afinitor) to treat advanced kidney cancer when other medicines have not been effective.
Lenvatinib is used together with Pembrolizumab (Keytruda) to treat a certain type of endometrial cancer (a type of uterine cancer) that has progressed and cannot be removed with surgery or radiation.
Lenvatinib is also used to treat liver cancer that cannot be removed with surgery.
Lenvatinib side effects
Get emergency medical help if you have signs of an allergic reaction to lenvatinib: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some people taking lenvatinib have developed a perforation (a hole or tear) or a fistula (an abnormal passageway) within the stomach or intestines. Call your doctor if you have severe stomach pain, or if you feel like you are choking and gagging when you eat or drink.
Also call your doctor at once if you have:
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common lenvatinib side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Lenvatinib
To make sure lenvatinib is safe for you, tell your doctor if you have ever had:
Lenvatinib may cause jaw bone problems (osteonecrosis). The risk is highest in people with cancer, blood cell disorders, pre-existing dental problems, or people treated with steroids, chemotherapy, or radiation. Ask your doctor about your own risk.
Lenvatinib may harm an unborn baby. You may need to have a negative pregnancy test before starting this treatment. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 30 days after your last dose.
Pregnancy may be less likely to occur while the mother or the father is using this medicine. Both men and women should still use birth control to prevent pregnancy because the medicine can harm an unborn baby.
Lenvatinib may affect fertility in men or women. Pregnancy could be harder to achieve while either parent is using this medicine.
Do not breastfeed while using this medicine, and for at least 1 week after your last dose.
How to use Lenvatinib
Usual Adult Dose for Thyroid Cancer:
24 mg orally once a day Comment: -Treatment should be continued until disease progression or unacceptable toxicity. Use: For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)
Usual Adult Dose for Renal Cell Carcinoma:
18 mg orally once a day Comments: -This drug is given in combination with 5 mg everolimus. -Refer to everolimus prescribing information for recommended dosing information. -Treatment should be continued until disease progression or unacceptable toxicity. Use: In combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy
Usual Adult Dose for Hepatocellular Carcinoma:
-Weight less than 60 kg: 8 mg orally once a day -Weight 60 kg or greater: 12 mg orally once a day Comment: -Treatment should be continued until disease progression or unacceptable toxicity. Use: For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
Usual Adult Dose for Endometrial Carcinoma:
20 mg orally once daily Comments: -This drug is given in combination with pembrolizumab 200 mg IV over 30 minutes every 3 weeks. -Refer to the pembrolizumab prescribing information for other dosing information. -Treatment should be continued until disease progression or unacceptable toxicity. Use: In combination with pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation
Warnings
Some people taking lenvatinib have developed a perforation (a hole or tear) or a fistula (an abnormal passageway) within the stomach or intestines. Get emergency medical help if you have severe stomach pain, or if you feel like you are choking and gagging when you eat or drink.
Call your doctor at once if you have signs of serious side effects, including: severe chest pain, shortness of breath, swelling in your ankles, numbness or weakness, confusion, severe headache, problems with speech or vision, seizure (convulsions), unusual bleeding, coughing up blood, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes).
What other drugs will affect Lenvatinib
Lenvatinib can cause a serious heart problem. Your risk may be higher if you also use certain other medicines for infections, asthma, heart problems, high blood pressure, depression, mental illness, cancer, malaria, or HIV.
Tell your doctor about all your other medicines, especially an osteoporosis medicine.
Other drugs may interact with lenvatinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions